Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Moderna, Inc.
New markets, a patent cliff, an M&A rebound and clinical trial catalysts. How will it all play out for the biopharma sector in 2024?
Pfizer held the number one spot on the Scrip 100 on the strength of its COVID-19 products, while some others faced challenging financial comparisons in 2022 because of COVID-19 headwinds.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
UK life sciences sector leaders are pleased to have attracted Flagship Pioneering to invest in the country, as its CEO Noubar Afeyan emphasizes that its initial focus would be on early ‘experiments’ in innovation and cultural bridge-building.
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
Drug Discovery Technologies
- Other Names / Subsidiaries
- Caperna LLC
- Moderna Therapeutics, Inc.
- Moderna LLC
- Newco LS18, Inc.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.